AVITA Medical, Inc.
RCEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.91 | -0.12 | 0.23 |
| FCF Yield | -17.59% | -11.35% | -11.89% | -6.35% |
| EV / EBITDA | -6.57 | -10.97 | -5.67 | -9.75 |
| Quality | ||||
| ROIC | -93.70% | -43.02% | -31.23% | -23.39% |
| Gross Margin | 85.85% | 84.48% | 82.45% | 81.52% |
| Cash Conversion Ratio | 0.79 | 1.07 | 0.72 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.13% | 14.94% | 5.60% | 32.30% |
| Free Cash Flow Growth | -47.68% | -101.16% | -5.89% | 31.58% |
| Safety | ||||
| Net Debt / EBITDA | -0.58 | -0.60 | 0.66 | 2.21 |
| Interest Coverage | -10.56 | -37.32 | 0.00 | -866.14 |
| Efficiency | ||||
| Inventory Turnover | 1.25 | 1.39 | 2.84 | 2.86 |
| Cash Conversion Cycle | 107.09 | 142.25 | -0.39 | 3.42 |